Search clinical trials for: Latanoprostene bunod 0.024% QD

Total 7 results

Bausch & Lomb Incorporated

Completed

Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT (JUPITER)

Ocular Hypertension | Glaucoma

United States
University of California, San Diego
Bausch & Lomb Incorporated

Completed

Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity

OAG - Open-Angle Glaucoma | OHT - Ocular Hypertension

United States
Bausch & Lomb Incorporated

Completed

Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers (KRONUS)

Intraocular Pressure

United States
Bausch & Lomb Incorporated

Withdrawn

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

Ocular Hypertension

United States
Bausch & Lomb Incorporated

Completed

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension (Voyager)

Intraocular Pressure

United States
Icahn School of Medicine at Mount Sinai

Completed

Nailfold Capillary Blood Flow With Latanoprost Bunod

Glaucoma, Open-Angle

United States
University of California, San Diego
Aerie Pharmaceuticals

Withdrawn

Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity

OAG - Open-Angle Glaucoma | OHT - Ocular Hypertension

3

Subscribe